Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy

키워드

참고문헌 (62)

1. Maceyka M, "Sphingolipid metabolites in inflammatory disease", Nature, 510, pp.58~67 (2014)
2. Merrill AH Jr, "Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics", Chem Rev, 111, pp.6387~6422 (2011)
3. Hannun YA, "Sphingolipids and their metabolism in physiology and disease", Nat Rev Mol Cell Biol, 19, pp.175~191 (2018)
4. Nixon GF, "Sphingolipids in inflammation : pathological implications and potential therapeutic targets", Br J Pharmacol, 158, pp.982~993 (2009)
5. Chitnis T, "CNS inflammation and neurodegeneration", J Clin Invest, 127, pp.3577~3587 (2017)
6. Brambilla R, "Neuroinflammation, the thread connecting neurological disease : Cluster : "Neuroinflammatory mechanisms in neurodegenerative disorders"", Acta Neuropathol, 137, pp.689~691 (2019)
7. Schwartz M, "The resolution of neuroinflammation in neurodegeneration : leukocyte recruitment via the choroid plexus", EMBO J, 33, pp.7~22 (2014)
8. Norris GT, "Immune cells and CNS physiology : Microglia and beyond", J Exp Med, 216, pp.60~70 (2019)
9. Arcuri C, "The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS", Front Mol Neurosci, 10, pp.191~ (2017)
10. Zhu M, "Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42Phagocytosis", Mol Neurobiol, 53, pp.2733~2749 (2016)
11. Kosicek M, "Phospholipids and Alzheimer's disease : alterations, mechanisms and potential biomarkers", Int J Mol Sci, 14, pp.1310~1322 (2013)
12. Assi E, "Sphingolipids and brain resident macrophages in neuroinflammation : an emerging aspect of nervous system pathology", Clin Dev Immunol, 2013, pp.309302~ (2013)
13. Liu Q, "Lipid metabolism in Alzheimer's disease", Neurosci Bull, 30, pp.331~345 (2014)
14. Yin F, "Energy metabolism and inflammation in brain aging and Alzheimer's disease", Free Radic Biol Med, 100, pp.108~122 (2016)
15. Davies L, "Sphingolipids in neuroinflammation", Handb Exp Pharmacol, 216, pp.421~430 (2013)
16. Mesa-Herrera F, "Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases : A Window for the Development of New Biomarkers", Int J Mol Sci, 20, pp.E3810~ (2019)
17. Di Pardo A, "Sphingolipid Metabolism : A New Therapeutic Opportunity for Brain Degenerative Disorders", Front Neurosci, 12, pp.249~ (2018)
18. Szepesi Z, "Bidirectional Microglia-Neuron Communication in Health and Disease", Front Cell Neurosci, 12, pp.323~ (2018)
19. Young MM, "Sphingolipids : regulators of crosstalk between apoptosis and autophagy", J Lipid Res, 54, pp.5~19 (2013)
20. Czubowicz K, "The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders", Mol Neurobiol, 56, pp.5436~5455 (2019)
21. Jęśko H, "The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling : Significance for Aging and Neurodegeneration", Mol Neurobiol, 56, pp.3501~3521 (2019)
22. Pahan K, "Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes", J Biol Chem, 273, pp.2591~2600 (1998)
23. Liu L, "Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1in primary neurons by sphingomyelinases", Neurobiol Aging, 34, pp.540~550 (2013)
24. de Wit NM, "Astrocytic ceramide as possible indicator of neuroinflammation", J Neuroinflammation, 16, pp.48~ (2019)
25. Jung JS, "Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide-stimulated microglia", Biochim Biophys Acta, 1831, pp.1016~1026 (2013)
26. Fischer I, "Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions", PLoS One, 6, pp.e23905~ (2011)
27. Grassi S, "Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases", Front Pharmacol, 10, pp.807~ (2019)
28. Karunakaran I, "Sphingosine 1-phosphate-A double edged sword in the brain", Biochim Biophys Acta Biomembr, 1859, pp.1573~1582 (2017)
29. Spiegel S, "The outs and the ins of sphingosine-1-phosphate in immunity", Nat Rev Immunol, 11, pp.403~415 (2011)
30. Wu YP, "Sphingosine kinase 1", S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease, 2008, pp.17, 2257~2264
31. Rothhammer V, "Control of autoimmune CNS inflammation by astrocytes", Semin Immunopathol, 37, pp.625~638 (2015)
32. Chalfant CE, "Sphingosine 1-phosphate and ceramide 1-phosphate : expanding roles in cell signaling", J Cell Sci, 118, pp.4605~4612 (2005)
33. Lee JY, "Neuronal SphK1acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease", Nat Commun, 9, pp.1479~ (2018)
34. Kalgutkar AS, "Aspirin-like molecules that covalently inactivate cyclooxygenase-2", Science, 280, pp.1268~1270 (1998)
35. Müller N, "COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders", Front Psychiatry, 10, pp.375~ (2019)
36. Serhan CN, "Pro-resolving lipid mediators are leads for resolution physiology", Nature, 510, pp.92~101 (2014)
37. Buckley CD, "Proresolving lipid mediators and mechanisms in the resolution of acute inflammation", Immunity, 40, pp.315~327 (2014)
38. Fullerton JN, "Lipid mediators in immune dysfunction after severe inflammation", Trends Immunol, 35, pp.12~21 (2014)
39. Mencarelli C, "Ceramide function in the brain : when a slight tilt is enough", Cell Mol Life Sci, 70, pp.181~203 (2013)
40. Graham WV, "Update on Alzheimer's Disease Therapy and Prevention Strategies", Annu Rev Med, 68, pp.413~430 (2017)
41. Cerquera-Jaramillo MA, "Visual Features in Alzheimer's Disease : From Basic Mechanisms to Clinical Overview", Neural Plast, 2018, pp.2941783~ (2018)
42. Heppner FL, "Immune attack : the role of inflammation in Alzheimer disease", Nat Rev Neurosci, 16, pp.358~372 (2015)
43. Visan I, "Alzheimer's disease microglia", Nat Immunol, 18, pp.876~ (2017)
44. Katsumoto A, "Microglia in Alzheimer's Disease : Risk Factors and Inflammation", Front Neurol, 9, pp.978~ (2018)
45. Jazvinšćak Jembrek M, "Ceramides in Alzheimer's Disease : Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation", Oxid Med Cell Longev, 2015, pp.346783~ (2015)
46. Couttas TA, "Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis", Acta Neuropathol Commun, 2, pp.9~ (2014)
47. Ceccom J, "Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease", Acta Neuropathol Commun, 2, pp.12~ (2014)
48. Salter MW, "Microglia emerge as central players in brain disease", Nat Med, 23, pp.1018~1027 (2017)
49. Ulland TK, "TREM2-a key player in microglial biology and Alzheimer disease", Nat Rev Neurol, 14, pp.667~675 (2018)
50. Fakhoury M, "Microglia and Astrocytes in Alzheimer's Disease : Implications for Therapy", Curr Neuropharmacol, 16, pp.508~518 (2018)
51. 김승현, "A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation", Dementia and Neurocognitive Disorders(대한치매학회지), 18(2), pp.33~46 (2019), 대한치매학회[DOI]
52. Alhouayek M, "COX-2-derived endocannabinoid metabolites as novel inflammatory mediators", Trends Pharmacol Sci, 35, pp.284~292 (2014)
53. Bertolini A, "Selective COX-2 inhibitors and dual acting anti-inflammatory drugs : critical remarks", Curr Med Chem, 9, pp.1033~1043 (2002)
54. Chiang N, "Aspirin triggers formation of anti-inflammatory mediators : New mechanism for an old drug", Discov Med, 4, pp.470~475 (2004)
55. Kotilinek LA, "Cyclooxygenase-2 inhibition improves amyloid-betamediated suppression of memory and synaptic plasticity", Brain, 131, pp.651~664 (2008)
56. Mitchell JA, "COX isoforms in the cardiovascular system : understanding the activities of non-steroidal anti-inflammatory drugs", Nat Rev Drug Discov, 5, pp.75~86 (2006)
57. Xu XM, "Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate", Proc Natl Acad Sci U S A, 96, pp.5292~5297 (1999)
58. Cuello AC, "Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?", Trends Pharmacol Sci, 38, pp.956~966 (2017)
59. Poewe W, "Parkinson disease", Nat Rev Dis Primers, 3, pp.17013~ (2017)
60. Engelender S, "The Threshold Theory for Parkinson's Disease", Trends Neurosci, 40, pp.4~14 (2017)
61. Charvin D, "Therapeutic strategies for Parkinson disease : beyond dopaminergic drugs", Nat Rev Drug Discov, 17, pp.844~ (2018)
62. McGregor MM, "Circuit Mechanisms of Parkinson's Disease", Neuron, 101, pp.1042~1056 (2019)

관련 논문AI추천